About Plex Pharmaceuticals
Plex Pharmaceuticals is a company based in San Diego (United States) founded in 2009 was acquired by Collidion in August 2017. Plex Pharmaceuticals offers products and services including Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors. Plex Pharmaceuticals operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter San Diego, United States
- SectorsHealthcare
- Email••••••••
- Website plexpharma.com
- Social LinkedIn Facebook
- Acquired by Collidion (Aug 2017)
- Legal Name Plex Pharmaceuticals, Incorporated
Products & Services of Plex Pharmaceuticals
Plex Pharmaceuticals offers a comprehensive portfolio of products and services, including Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors.
Modulators for heat shock proteins to treat Parkinson's and ALS diseases.
Compounds that enhance alpha-crystallin activity to prevent cataract formation.
Inhibitors of HSP90 and TRAP-1 for treating glioblastoma and brain tumors.
Funding Insights of Plex Pharmaceuticals
- Total Rounds 10
- Last Round Grant — $298,590
- First Round $201,930
(Apr 2010)
- Investors Count 4
All 10 funding rounds of Plex Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $298,590 | Grant | – | – | |
| Feb 2020 | $600,000 | Grant | – | – | |
| Feb 2020 | $600,000 | Grant | – | – | |
| Sep 2016 | $299,173 | Grant | – | – | |
| Sep 2016 | $1.61M | Grant | – | – | |
| Jul 2016 | $670,865 | Grant | – | – | |
| May 2014 | $599,959 | Grant | – | – | |
| Sep 2010 | $279,068 | Grant | – | – | |
| May 2010 | $201,930 | Grant | – | – | |
| Apr 2010 | $201,930 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Plex Pharmaceuticals
Plex Pharmaceuticals has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include HHS, The Michael J. Fox Foundation and Collidion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | niaid.nih.gov | - | |
Vision research is conducted to eliminate vision loss. | – | nei.nih.gov | Bethesda, United States | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
Early-stage healthcare research is licensed for product development. | 2015 | collidion.com | Petaluma, United States |
Investor details for Plex Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Plex Pharmaceuticals
4 people are tracked at Plex Pharmaceuticals (3 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Hoji Alimi | Chairman & CEO | Leadership |
William H. Watson, III | VP, Business Development | Leadership |
Sameer Harish | Director, Finance | Leadership |
Nicholas Dp Cosford | Scientific Advisor | Board & advisors |
Complete people profiles for Plex Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Plex Pharmaceuticals
4 dated milestones of Plex Pharmaceuticals across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Plex Pharmaceuticals is founded.
- Funding First funding round of $202K.
- Exit Acquired by Collidion.
- Funding Latest funding round, Grant, of $299K.
Competitors of Plex Pharmaceuticals
Plex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| entradatx.com | 2016 | Boston, United States | $175.25M | 122 | Biologics platform developed for intracellular delivery in rare diseases. | |
| adamaspharma.com | 2002 | Emeryville, United States | $68.03M | 142 | Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. | |
| sonomabio.com | 2012 | San Francisco, United States | $335M | 74 | T-cell-based therapies for autoimmune and degenerative diseases are developed. | |
| juvlabs.com | 2017 | Dublin, Ireland | $289.89M | – | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| bluerocktx.com | 2016 | Boston, United States | $225M | 138 | Stem cell therapies are developed for cardiovascular and neurological diseases. | |
| vergegenomics.com | 2015 | San Francisco, United States | $134.5M | 38 | Neurodegenerative disease drugs are developed using computational genomics. |
Detailed competitors of Plex Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Plex Pharmaceuticals
The website of Plex Pharmaceuticals (plexpharma.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 37.2% vs previous month
Latest news on Plex Pharmaceuticals
Complete news archive for Plex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Plex Pharmaceuticals
10 companies that operate in the same segment as Plex Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Plex Pharmaceuticals
Plex Pharmaceuticals was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Plex Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Plex Pharmaceuticals (formerly CalAsia Pharmaceuticals), an early stage biotechnology company is focussed on discovering small molecules for diseases caused by protein misfolding such as Amyotrophic lateral sclerosis (ALS), Parkinsons disease. Its technology platform combines functional fragment screening with X-ray crystallography co-crystallization guided by structure-based design approach to design and synthesize New Chemical Entities (NCEs) with drug-like properties. Its discovery programs include modulators of heat shock proteins (Hsp) and FK506 Binding Protein (FKBP) for the treatment of Parkinsons disease (PD) and Amyotrophic lateral sclerosis (ALS); small molecule for the treatment of Glioblastoma multiforme. The company also has discovery and preclinical programs for Zika, Dengue, and West nile virus.
Plex Pharmaceuticals's top competitors include Alector, Entrada Therapeutics and Annexon.
Plex Pharmaceuticals offers Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors.
Plex Pharmaceuticals has 5 investors. Key investors include HHS, The Michael J. Fox Foundation, Collidion, NIAID, and National Eye Institute.
Plex Pharmaceuticals operates through Plex Pharmaceuticals, Incorporated.
Yes. Plex Pharmaceuticals was acquired by Collidion in August 2017.